Heidi Klepin to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Heidi Klepin has written about Antimetabolites, Antineoplastic.
Connection Strength
0.037
-
Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):E49-E52.
Score: 0.037